Swissmedic Accepts Marketing Authorization Application for Piflufolastat (18F) for Prostate Cancer

Swissmedic has accepted for review a marketing authorization application seeking the approval of Piflufolastat (18F) for prostate cancer.

Related Keywords

Switzerland ,United States ,Swiss ,Benoit Woessmer ,Michel Wuillemin ,Swiss Agency For Therapeutic Products Swissmedic ,Lantheus Holdings Inc ,Swiss Agency ,Therapeutic Products ,European Medicines Agency ,European Commission ,Lantheus Holdings ,Clin Cancer ,Global Oncology ,Prostate Cancer ,News ,